June 2026
Serotonin
What June 2026's 15 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 15 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
In June 2026, serotonin research focused on the 5-HT2A receptor's role in mediating psychedelic effects and therapeutic potential, with studies finding that mGluR2 does not directly interact with 5-HT2A receptors, that 5-HT2B receptors are necessary for psilocybin's antidepressant-like effects in rats, and that psilocybin can restore 5-HT2A signaling after traumatic brain injury. Results were generally consistent across studies, but the evidence is limited by small sample sizes, preclinical models, and a lack of human trials for many findings.
Confidence in the evidence
Low-Moderate- Most studies are preclinical (rodent models) or in vitro, with only one meta-analysis and one clinical reanalysis included.
- Sample sizes are small (e.g., N=266, N=654, N=1,100 in meta-analysis; rat studies with limited numbers).
- Findings are consistent in direction (e.g., no direct 5-HT2A-mGluR2 interaction, 5-HT2B role in psilocybin effects), but replication in humans is lacking.
- Risk of bias is present due to open-label designs, lack of blinding in some studies, and reliance on animal models.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| No evidence for direct physical interaction of 5-HT 2A -mGluR2 receptors in vitro or in vivo 2026 | preclinical (in vitro and in vivo) | — | Opposes | No evidence for direct physical interaction between mGluR2 and 5-HT2A receptors in vitro or in vivo, supporting a presynaptic inhibition model. |
| Skin on Drugs: Psychotropic Compounds in Cutaneous Biology 2026 | review | — | Supports | Psychedelics acting as serotonin receptor agonists may influence cellular aging and immune modulation, with psilocybin reducing aging markers in human fibroblasts. |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine Maintains Neuroplasticity 2026 | theoretical review | — | Mixed | Evidence for DMT's role in maintaining neuroplasticity is mixed and contested, with conflicting reports on DMT concentrations in the brain. |
| The Architecture of Ego Dissolution: A Mechanical-First Evaluation of N,N-Dimethyltryptamine at the Sigma-1 and 5-HT2A Interfaces 2026 | theoretical | — | Unclear | Abstract not provided; cannot determine direction. |
| Synthesis and BiologicalEvaluation of 4‑Bromo-N,N-dimethyltryptamine(4-Br-DMT): A Synthetic BuildingBlock for Future Analog Development 2026 | preclinical (in vitro and in vivo) | — | Mixed | 4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT. |
| Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test 2026 | preclinical (in vivo) | — | Supports | Blocking 5-HT2B receptors abolished both rapid and sustained antidepressant-like effects of psilocybin in the forced swim test, without affecting head-twitch response. |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine has Endogenous Functions 2026 | theoretical review | — | Mixed | Evidence for endogenous DMT functions is mixed and contested, with conflicting reports on DMT concentrations and receptor affinities. |
| The Effects of Serotonergic systems on Cognitive Flexibility and Perseverative Thinking: a comparison between SSRI, classical psychedelics, and acute tryptophan depletion in a Multilevel Meta-Analysis 2026 | meta-analysis | 2030 | No effect | Serotonergic interventions (ATD, SSRIs, psychedelics) did not significantly affect cognitive flexibility or perseverative thinking. |
| Decoding the serotonin–alcohol crosstalk: the role of central serotonergic dysregulation in alcohol use disorder 2026 | review | — | Supports | Central serotonergic dysregulation is implicated in alcohol use disorder, with reduced 5-HT activity increasing vulnerability, and psychedelic-assisted therapies showing potential. |
| Psychedelics and related compounds in cluster headache and migraine: a systematic review and meta-analysis v1 2026 | protocol for systematic review and meta-analysis | — | Unclear | Protocol describes a planned systematic review on serotonergic psychedelics for cluster headache and migraine; no results yet. |
| Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects. 2026 | review | — | Supports | Serotonergic psychedelics may modulate core pathways in autism spectrum disorder by enhancing neuroplasticity and reducing neuroinflammation. |
| Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes 2026 | RCT reanalysis | — | Mixed | Women receiving psilocybin showed greater reductions in anxiety than men, while women receiving escitalopram showed greater reductions in anhedonia; sexual dysfunction was lower with psilocybin. |
| Serotonin 2A receptor binding, functional activity, and in vitro metabolism of two trideuteromethoxy 2C-B isotopologues. 2026 | preclinical (in vitro) | — | Supports | Deuteration of 2C-B increased affinity at 5-HT2A receptors but did not affect functional activity or metabolism. |
| Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats. 2026 | preclinical (in vivo) | — | Supports | Psilocybin improved sensorimotor function, restored 5-HT2A binding, and reduced microglial cell counts after chronic TBI. |
| Enhanced effect of the hallucinogen DOI in L-DOPA receptor Gpr143-deficient mice. 2026 | preclinical (in vivo and in vitro) | — | Supports | GPR143 negatively regulates 5-HT2A receptor signaling, and its deficiency enhances behavioral responses to the hallucinogen DOI. |
No evidence for direct physical interaction between mGluR2 and 5-HT2A receptors in vitro or in vivo, supporting a presynaptic inhibition model.
preclinical (in vitro and in vivo)
Psychedelics acting as serotonin receptor agonists may influence cellular aging and immune modulation, with psilocybin reducing aging markers in human fibroblasts.
review
Evidence for DMT's role in maintaining neuroplasticity is mixed and contested, with conflicting reports on DMT concentrations in the brain.
theoretical review
Abstract not provided; cannot determine direction.
theoretical
4-Br-DMT has a serotonergic profile without psychedelic-like effects in mice but has a reduced safety profile compared to psilocin and DMT.
preclinical (in vitro and in vivo)
Blocking 5-HT2B receptors abolished both rapid and sustained antidepressant-like effects of psilocybin in the forced swim test, without affecting head-twitch response.
preclinical (in vivo)
Evidence for endogenous DMT functions is mixed and contested, with conflicting reports on DMT concentrations and receptor affinities.
theoretical review
Serotonergic interventions (ATD, SSRIs, psychedelics) did not significantly affect cognitive flexibility or perseverative thinking.
meta-analysis · Sample size: 2030
Central serotonergic dysregulation is implicated in alcohol use disorder, with reduced 5-HT activity increasing vulnerability, and psychedelic-assisted therapies showing potential.
review
Protocol describes a planned systematic review on serotonergic psychedelics for cluster headache and migraine; no results yet.
protocol for systematic review and meta-analysis
Serotonergic psychedelics may modulate core pathways in autism spectrum disorder by enhancing neuroplasticity and reducing neuroinflammation.
review
Women receiving psilocybin showed greater reductions in anxiety than men, while women receiving escitalopram showed greater reductions in anhedonia; sexual dysfunction was lower with psilocybin.
RCT reanalysis
Deuteration of 2C-B increased affinity at 5-HT2A receptors but did not affect functional activity or metabolism.
preclinical (in vitro)
Psilocybin improved sensorimotor function, restored 5-HT2A binding, and reduced microglial cell counts after chronic TBI.
preclinical (in vivo)
GPR143 negatively regulates 5-HT2A receptor signaling, and its deficiency enhances behavioral responses to the hallucinogen DOI.
preclinical (in vivo and in vitro)
Points of agreement
- Multiple studies support the role of 5-HT2A receptors in mediating psychedelic effects and therapeutic potential.
- Preclinical evidence consistently shows that psilocybin can modulate neuroplasticity and reduce neuroinflammation.
- The meta-analysis found no significant effect of serotonergic interventions on cognitive flexibility or perseverative thinking.
Conflicts
- Evidence for endogenous DMT functions is mixed, with conflicting reports on DMT concentrations in the brain (nM range vs. below detection limit).
- The role of specific 5-HT receptor subtypes in antidepressant effects is debated: one study implicates 5-HT2B receptors, while others focus on 5-HT2A.
Gaps
- Lack of human clinical trials for many findings, especially for TBI, autism, and headache disorders.
- Durability of effects and long-term safety of psychedelic treatments are not addressed.
- Sex-specific effects are understudied; only one reanalysis examined sex differences.
- Dose-response relationships and optimal dosing regimens are not established.
- Mechanisms of action (e.g., direct vs. indirect receptor interactions) remain unclear.